TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7137070
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (300 mg daily)
Study: 15125213
Drug: Steroids combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids combined with thyroxine
Study: 15125213
Drug: Steroids only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids only
Study: 12207869
Drug: Carbatrol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbatrol (2 x 200 mg capsules), b.i.d. for 5 days
Study: 12207869
Drug: Tegretol‐XR (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegretol‐XR (400 mg), b.i.d. for 5 days
Study: 9427920
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus iontophoresis of calcitonin gene‐related peptide and vasoactive intestinal polypeptide
Study: 9427920
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus placebo iontophoresis
Study: 8085219
Drug: Fluoridated toothpicks
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated toothpicks (0.80 mg F as NaF)
Study: 8085219
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg F tablet (Fludent)
Study: 31559483
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of medical therapy with sacubitril/valsartan, ivabradine, or both after CRT implantation
Study: 29231603
Drug: Warm-needling moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm-needling moxibustion treatment for KOA, 40 min per treatment, 12 treatments over 3 weeks.
Study: 29231603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 3 weeks).
Study: 29231603
Drug: Warm-needling moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm-needling moxibustion treatment for KOA.
Study: 25957107
Drug: Taikong Yangxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taikong Yangxin (Chinese herbal medicine)
Study: 23677418
Drug: Vaginal ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal ascorbic acid (250 mg tablets vaginally at bedtime once a day for 6 days, followed by one tablet per week for 12 weeks)
Study: 11200381
Drug: Amoxicillin-clavulanate (ACA)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (ACA) for 5 days
Study: 11200381
Drug: Amoxicillin-clavulanate (ACA)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (ACA) for 10 days
Study: 11200381
Drug: Amoxicillin-clavulanate (ACA)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (ACA) for 5 days and 10 days
Study: 9311208
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol-fentanyl-ketamine (PFK)
Study: 3596768
Drug: Hydrochlorothiazide (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25‐50 mg b.i.d.)
Study: 3596768
Drug: Diltiazem (120‐180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120‐180 mg b.i.d.)
Study: 31236782
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices (SCDs) applied to the arm harboring the PICC
Study: 31236782
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices (SCDs) applied to the arm harboring the PICC (after accounting for crossovers)
Study: 30702019
Drug: Deutetrabenazine dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine dosed 24-48 mg/day
Study: 28489298
Drug: ALA‐PDT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA‐PDT plus cetirizine 10 mg (n=10)
Study: 22907731
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) treatment in blacks
Study: 18489017
Drug: therapist-delivered CRA
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapist-delivered CRA treatment with vouchers
Study: 18489017
Drug: computer-assisted CRA
Normalized name: CRA-028129
DrugBank: CRA-028129 (DB05951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: computer-assisted CRA treatment with vouchers
Study: 11865833
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 1800 mg daily
Study: 9741018
Drug: Intravenous corticotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticotrophin (ACTH) 120 U/day
Study: 9741018
Drug: Hydrocortisone 300
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 300 mg/day
Study: 8275731
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 40 mg/kg/d, intravenously for 3 days
Study: 2500462
Drug: Flunitrazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (2 mg intravenously)
Study: 29957136
Drug: Spatone supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatone supplement
Study: 21639596
Drug: Alcohol (0.82
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.82 g/kg males; 0.74 g/kg females)
Study: 19528265
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ceftazidime (200 mg/kg of body weight/day)
Study: 19528265
Drug: Short infusions
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusions of ceftazidime (200 mg/kg of body weight/day)
Study: 11349744
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ceftazidime
Study: 19528265
Drug: Short infusions
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusions of ceftazidime
Study: 3182964
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose calcitriol (≤ 0.50 micrograms/day)
Study: 19040806
Drug: Papacárie gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papacárie gel (chemomechanical caries removal agent)
Study: 21175439
Drug: oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: oseltamivir 75 mg twice daily for 4.5 days
Study: 11304904
Drug: warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin alone
Study: 21175439
Drug: oseltamivir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: oseltamivir + warfarin
Study: 18723329
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic lock therapy
Study: 18723329
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous administration of antibiotics
Study: 14585939
Drug: ximelagatran (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran (24 mg, taken twice daily for 18 months)
Study: 10972907
Drug: G‐CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (300 microg filgrastim) given three times weekly for 12 weeks
Study: 9526580
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 mg/kg) following PBPC infusion
Study: 8317948
Drug: 2‐deoxyglucose (2DG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐deoxyglucose (2DG) 50 mg/kg
Study: 31692226
Drug: Exenatide (EXE)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EXE) once weekly + dapagliflozin (DAPA) once daily
Study: 31692226
Drug: Exenatide (EXE)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EXE) once weekly + placebo (PLB)
Study: 26535593
Drug: Febuxostat 40-80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 40-80 mg daily
Study: 26535593
Drug: Allopurinol 100-300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100-300 mg daily
Study: 18206734
Drug: 1997 ADA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1997 ADA IFG definition (fasting plasma glucose 110 to 125 mg/dl)
Study: 18206734
Drug: 2003 ADA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2003 ADA IFG definition (fasting plasma glucose 100 to 125 mg/dl)
Study: 7986706
Drug: Control (ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ICE chemotherapy without IL‐3)
Study: 2525397
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with medroxyprogesterone acetate at high dosage (HD‐MPA; 500 mg IM per day times 28 or 500 mg i.m. 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months
Study: 4883651
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive with low oestrogen/progestogen content
Study: 4883651
Drug: Identical dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical dummy tablets (control)
Study: 19556318
Drug: Trabectedin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.5 mg/m2 24 h (arm A)
Study: 19556318
Drug: Trabectedin 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.3 mg/m2 3 h (arm B)
Study: 14718678
Drug: Levodopa combined
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa combined with COMT inhibitor entacapone
Study: 9885092
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention consisting of 35 weekly, 2 h sessions of supportive plus cognitive behavioral therapy; n = 30
Study: 30864473
Drug: Paracetamol compliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol compliance
Study: 30864473
Drug: Oxycodone immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone immediate release (IR) compliance
Study: 30864473
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR quantity compliance
Study: 17381566
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% (20 ml)
Study: 12363117
Drug: Fluvoxamine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (median dose 150 mg, range 50-300 mg)
Study: 1103574
Drug: Maprotiline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline and Amitriptyline (both drugs)
Study: 30811280
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1)
Study: 30811280
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3)
Study: 27007714
Drug: Engage in
Normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engage in Education‐London (EiE‐L) intervention, delivered over 12 weeks
Study: 23695652
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (OMT) including lifestyle intervention and intensive secondary prevention with proven pharmacotherapies
Study: 14583439
Drug: Protocol 2
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2 (6 h of mild hyperglycemia, approximately 7 mmol/l)
Study: 14583439
Drug: Protocol 1
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1 (glucose varied to mimic a postprandial pattern, peak glucose approximately 11.1 mmol/l)
Study: 9415507
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic treatment
Study: 8395380
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily
Study: 3706840
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 3 ml 0.5% bupivacaine in isobaric solution
Study: 21919060
Drug: Sertraline responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline responders
Study: 21919060
Drug: Sertraline non-responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline non-responders
Study: 20206786
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3, 9, and 15 mg/d; 6, 9, and 12 mg/d; 6 and 12 mg/d)
Study: 16266859
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg n-3 PUFA + 700 mg canola oil
Study: 16266859
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g canola oil (control)
Study: 12019663
Drug: Fluoxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-60 mg daily)
Study: 10466664
Drug: Community-wide oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide oral azithromycin treatment (three doses with intervals of 1 week)
Study: 10466664
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical tetracycline (once daily for 6 weeks)
Study: 3918426
Drug: Intracoronary thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary thrombolytic therapy with streptokinase (STK)
Study: 3918426
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and intracoronary and intravenous nitroglycerin (NTG group)
Study: 31554937
Drug: Esaxerenone monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone monotherapy
Study: 31554937
Drug: Esaxerenone with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone with RAS inhibitor
Study: 25533646
Drug: Mesalazine, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine, 800 mg, three times daily for 12 weeks
Study: 25533646
Drug: Placebo, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, three times daily for 12 weeks
Study: 23566712
Drug: Balanced electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced electrolyte solution
Study: 19114201
Drug: Single-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefazolin (2 g)
Study: 19114201
Drug: 24-hour treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour treatment of cefazolin (2-g initial dose, followed by 1 g every 8 hours)
Study: 12828083
Drug: Twice-a-day interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day interferon-beta (3 MU) for 3 weeks followed by once-a-day interferon-beta (6 MU) for 5 weeks (group A)
Study: 12828083
Drug: Twice-a-day interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day interferon-beta (group A)
Study: 11074884
Drug: 131I-lipiodol (1110-MBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I-lipiodol (1110-MBq dose) administered into the hepatic artery
Study: 79319
Drug: 2-month initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily thiacetazone and isoniazid
Study: 79319
Drug: 1-month initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Study: 79319
Drug: Total duration
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total duration of chemotherapy increased from 6 months to 8 months
Study: 29097166
Drug: Active product
Normalized name: collagen,activated Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active product (125 mL once-a-day drink containing Fortasyn Connect)
Study: 25399241
Drug: Weekly acupuncture
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly acupuncture treatment (n = 118)
Study: 25399241
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine tartrate 2 mg twice daily (n = 122)
Study: 21680210
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine 0.25 mg/kg body weight
Study: 16935098
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (2 g as an intravenous bolus before sternotomy)
Study: 10889591
Drug: Subcutaneous IL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IL‐2 (7.5 mIU twice per day in 5-day courses every 8 weeks) + ART
Study: 10889591
Drug: Subcutaneous IL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IL‐2 + ART
Study: 9096917
Drug: Fluvastatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (30 mg/day) added to probucol treatment for 12 weeks
Study: 9096917
Drug: Fluvastatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (30 mg/day)
Study: 9690694
Drug: Intravenous mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mCPP (0.1 mg/kg)
Study: 8420593
Drug: Intravenous mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mCPP
Study: 8420593
Drug: Oral mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mCPP
Study: 8420593
Drug: Metergoline pretreatment
Normalized name: Metergoline
DrugBank: Metergoline (DB13520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline pretreatment prior to intravenous mCPP
Study: 2868029
Drug: dipyridamole (Persantine)
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dipyridamole (Persantine) plus aspirin
Study: 19891665
Drug: CB-01-05 MMX
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-01-05 MMX 210 mg tablets
Study: 16427529
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg bolus over 10 minutes, followed by continuous infusion at 1 mg/kg per hour)
Study: 12873935
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 0.2 mg/kg followed by propofol infusion
Study: 12873935
Drug: IV normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline (placebo) followed by propofol 1%/lidocaine 1% mixture infusion
Study: 8915224
Drug: Low-dose ANP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ANP (3 pmol/kg/min)
Study: 8915224
Drug: Low-dose BNP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BNP (3 pmol/kg/min)
Study: 8915224
Drug: High-dose ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ANP (10 pmol/kg/min)
Study: 8915224
Drug: High-dose BNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BNP (10 pmol/kg/min)
Study: 8915224
Drug: Low-dose ANP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ANP
Study: 8915224
Drug: High-dose ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ANP
Study: 8915224
Drug: Low-dose BNP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BNP
Study: 8915224
Drug: High-dose BNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BNP
Study: 1860210
Drug: Biphasic waveform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic waveform defibrillation (RV-LV epicardial patches)
Study: 6341017
Drug: Maximized insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximized insulin treatment
Study: 26915009
Drug: Autologous Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Protein Solution (APS)
Study: 26792933
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg twice a day for 24 weeks
Study: 24557078
Drug: Baseline bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline bilirubin level of 0.5 mg/dl or higher with hemoglobin concentrations of 14 g/dl or higher
Study: 24557078
Drug: Baseline bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline bilirubin level <0.5 mg/dl with hemoglobin concentration <14 g/dl
Study: 22897752
Drug: Carboplatin/paclitaxel (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/paclitaxel (AUC 5/6; 200 mg/m(2))
Study: 11457553
Drug: DTPa-HBV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV/Hib vaccine administered as a single injection (Group 1)
Study: 11457553
Drug: DTPa-HBV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV and Hib vaccines administered simultaneously at separate sites (Group 2)
Study: 9734938
Drug: TNF alpha
Normalized name: TNF alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF alpha MAb (7.5 mg/kg)
Study: 3289293
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (twice daily injections)
Study: 29956440
Drug: Topical EGF
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical EGF ointment
Study: 26583667
Drug: LCT-EOS >3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT-EOS >3 mmol/L
Study: 19674280
Drug: Human intravenous
Normalized name: Glassia, human intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human intravenous immunoglobulin (hIVIG) 0.5 g/kg